NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment option for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company cited the absence of approved vaccines or therapies specifically targeting the virus strain, highlighting an urgent need for effective interventions.
The company stated that NV-387’s host-targeted antiviral mechanism and oral formulation could offer potential advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. Unlike many antiviral drugs that directly target viral proteins, NV-387 is designed to modulate host cell processes, potentially reducing the likelihood of viral resistance and broadening its activity against multiple viruses.
NV-387 is already being prepared for a Phase II clinical trial in the Democratic Republic of Congo for mpox (formerly known as monkeypox). This ongoing development could support near-term regional availability if the drug is found effective against Ebola. NanoViricides noted that the drug’s broad-spectrum activity and oral administration make it a practical candidate for use in resource-limited settings and outbreak zones.
The Bundibugyo strain of Ebola virus has caused sporadic outbreaks in Africa, with the most recent one expanding rapidly. The lack of approved vaccines or specific treatments for this strain poses a significant public health challenge. According to the World Health Organization, Ebola virus disease has a high fatality rate, and containing outbreaks often requires swift deployment of medical countermeasures.
NanoViricides’ lead drug candidate NV-387 is a nanoviricide designed to target a broad range of viruses, including respiratory syncytial virus (RSV), COVID-19, influenza, and mpox. The company’s technology platform, based on TheraCour’s nanomedicine technology, enables the development of antiviral nanomaterials that can encapsulate drugs or act independently.
The company’s business model involves licensing technology from TheraCour Pharma Inc. for specific viral applications. NanoViricides holds exclusive licenses for drugs targeting HIV/AIDS, hepatitis B and C, rabies, herpes simplex, varicella-zoster, influenza, dengue, Japanese encephalitis, West Nile, Ebola/Marburg, and certain coronaviruses.
As with any drug development effort, there is no guarantee that NV-387 will prove effective against Ebola in humans. The company acknowledges that the path to drug development is lengthy and requires substantial capital. However, the potential for NV-387 to address an unmet medical need in the Bundibugyo outbreak underscores the importance of continued research and clinical evaluation.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/aSF5Z.
